Background: Recent studies indicate that N6-methyladenosine (mA) RNA modification may regulate ferroptosis in cancer cells, while its molecular mechanisms require further investigation.
Methods: Liquid Chromatography-Tandem Mass Spectrometry (HPLC/MS/MS) was used to detect changes in mA levels in cells. Transmission electron microscopy and flow cytometry were used to detect mitochondrial reactive oxygen species (ROS). RNA sequencing (RNA-seq) was employed to analyze the factors regulating ferroptosis. Chromatin immunoprecipitation (ChIP) was used to assess the binding of regulatory factors to the SLC7A11 promoter, and a Dual-Luciferase reporter assay measured promoter activity of SLC7A11. The dmACRISPR system was utilized for the demethylation of specific transcripts. The Cancer Genome Atlas Program (TCGA) database and immunohistochemistry validated the role of the METTL3/SLC7A11 axis in cancer progression.
Results: The mA methyltransferase METTL3 was upregulated during cancer cell ferroptosis and facilitated erastin-induced ferroptosis by enhancing mitochondrial ROS. Mechanistic studies showed that METTL3 negatively regulated the transcription and promoter activity of SLC7A11. Specifically, METTL3 induced H3K27 trimethylation of the SLC7A11 promoter by suppressing the mRNA stability of H3K27 demethylases KDM6B. Furthermore, METTL3 suppressed the expression of GATA3, which regulated SLC7A11 transcription by binding to the putative site at - 597 to - 590 of the SLC7A11 promoter. METTL3 decreased the precursor mRNA stability of GATA3 through mA/YTHDF2-dependent recruitment of the 3'-5' exoribonuclease Dis3L2. Targeted demethylation of KDM6B and GATA3 mA using the dmACRISPR system significantly increased the expression of SLC7A11. Moreover, the transcription factor YY1 was responsible for erastin-induced upregulation of METTL3 by binding to its promoter-proximal site. In vivo and clinical data supported the positive roles of the METTL3/SLC7A11 axis in tumor growth and progression.
Conclusions: METTL3 regulated the transcription of SLC7A11 through GATA3 and KDM6B to modulate ferroptosis in an mA-dependent manner. This study provides a novel potential strategy and experimental support for the future treatment of cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1186/s12929-024-01100-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
N6-methyladenosine RNA modification regulates the transcription of SLC7A11 through KDM6B and GATA3 to modulate ferroptosis.
J Biomed Sci
January 2025
Guangdong Provincial Key Laboratory of New Drug Design and Evaluation, State Key Laboratory of Anti-Infective Drug Discovery and Development, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, 510006, China.
Background: Recent studies indicate that N6-methyladenosine (mA) RNA modification may regulate ferroptosis in cancer cells, while its molecular mechanisms require further investigation.
Methods: Liquid Chromatography-Tandem Mass Spectrometry (HPLC/MS/MS) was used to detect changes in mA levels in cells. Transmission electron microscopy and flow cytometry were used to detect mitochondrial reactive oxygen species (ROS).
Downregulation of FcRn promotes ferroptosis in herpes simplex virus-1-induced lung injury.
Cell Mol Life Sci
January 2025
School of Basic Medical Sciences, Xinxiang Medical University, #601 Jinsui Road, Xinxiang, 453003, Henan, China.
Article Synopsis
- HSV-1 infection can lead to lung injury, and a study found that lower levels of FcRn (a protein) are linked to more severe lung damage caused by the virus.
- The study revealed that HSV-1 increases the methylation of the FcRn gene, which reduces its expression by promoting DNMT3b, a protein that inhibits transcription through a specific region of the FcRn promoter.
- Inhibiting ferroptosis (a type of cell death) with a drug helped reduce lung injury in cases affected by HSV-1, indicating that targeting FcRn might be a promising therapeutic approach.
[Roles of ferroptosis in the development of diabetic nephropathy].
Zhejiang Da Xue Xue Bao Yi Xue Ban
December 2024
Department of Endocrinology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China.
Article Synopsis
- Diabetic nephropathy is a serious complication of diabetes that can lead to death, and ferroptosis (an iron-dependent cell death process) plays a role in its progression.
- AMPK signaling can slow down diabetic nephropathy but excessive activation may cause autophagic death, while Nrf2 and HO-1 pathways can protect against ferroptosis; however, these pathways have complex effects.
- Other factors like TGF-β1 and specific exosome-related signals also contribute to the development of diabetic nephropathy, suggesting potential new therapeutic targets to prevent or treat this condition.
Lipoxin A4 suppresses neutrophil extracellular traps formation through the FPR2-dependent regulation of METTL3 in ischemic stroke.
Brain Res Bull
January 2025
Department of Neurology, Shanghai Tenth People's Hospital Chongming Branch, 2866 Chongming Road, Shanghai 202157, China.
Background: This study aimed to clarify whether the neuroprotective effect of LXA4 is associated with the targeting of neutrophil extracellular traps (NETs) in ischemic stroke (IS).
Methods: The MCAO rat model was established to assess cerebral infarction, brain water content and neurological deficits. ELISA was employed to examine the activities of MPO, NE, MMP-9.
Regulatory factor X1 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by transcriptional regulation of BECN1.
Cell Oncol (Dordr)
December 2024
State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Article Synopsis
- Sorafenib is a first-line drug for advanced hepatocellular carcinoma (HCC), which shows limited effectiveness, but may induce cell death through a process called ferroptosis.
- The study identified a key regulatory factor, RFX1, that enhances ferroptosis in HCC cells by inhibiting a specific antiporter system and regulating the expression of the BECN1 gene.
- Findings suggest a new signaling loop involving STAT3 that promotes RFX1 expression and helps explain how sorafenib leads to HCC cell death, offering insights for potential therapeutic strategies.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!